Related Experiment Videos
Laura Bounaix1, Mohammed Bendouda1, Jacques-Olivier Bay1
1Clermont Université; Clermont Université, université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
Abstract:
ANTI-PD-1 ANTIBODIES THERAPEUTIC USE IN LYMPHOID NEOPLASMS: Immune checkpoints blockade is under investigation in oncology, and has demonstrated its clinical efficacy. In hematology, immune checkpoints blockade is in earlier stages of development, but there are strong evidences of PD-1 blockade anti-tumor efficacy in some lymphoid malignancies. In this review, we will discuss the main clinical results of PD-1 inhibitors in lymphoid neoplasms and the main perspectives of development.
Insights
Anti-PD-1 antibodies show promise in treating lymphoid cancers. This review covers current clinical results and future directions for PD-1 blockade therapy in lymphoid neoplasms.
Area of Science:
- Oncology
- Hematology
- Immunotherapy
Background:
- Immune checkpoint blockade is a developing area in oncology.
- PD-1 blockade has shown anti-tumor efficacy in certain lymphoid malignancies.
Purpose of the Study:
- To review the clinical efficacy of anti-PD-1 antibodies in lymphoid neoplasms.
- To discuss the future development of PD-1 inhibitors in hematologic malignancies.
Main Methods:
- Literature review of clinical studies on PD-1 inhibitors.
- Analysis of current data on PD-1 blockade in lymphoid neoplasms.
Main Results:
- PD-1 inhibitors demonstrate clinical efficacy in specific lymphoid malignancies.
- Evidence supports the anti-tumor activity of PD-1 blockade in hematology.
Conclusions:
- Anti-PD-1 antibodies are a promising therapeutic strategy for lymphoid neoplasms.
- Further research is warranted to optimize PD-1 inhibitor development in hematologic cancers.